BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

Dexcom provided a look at new data for the upcoming generation of its continuous glucose monitoring sensor. Presenting at the J.P. Morgan Healthcare Conference, the details were pulled from a large ...

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

(Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. Stelo was cleared by the U.S. health ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

DexCom, Inc. DXCM reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents ...